irinotecan

Some people are genetically more likely to have certain side effects from irinotecan.

Your doctor or pharmacist can provide more information about irinotecan.

This list is not complete and other drugs may interact with irinotecan.

You may need to keep using these medications for at least a day after your irinotecan injection.

These patients generally cannot tolerate or have not responded to another drug called irinotecan.

In addition, the agency said, the trial did not adequately show that irinotecan, which has serious side effects, was even needed.

You should not use irinotecan if you are allergic to it.

In Japan, the first line treatment is shifting to irinotecan and cisplatin.

If you need surgery, tell the surgeon ahead of time that you are using irinotecan.

There is some evidence of its effectiveness to prevent diarrhea in cancer patients who have received irinotecan.

The results of the earlier, rejected studies were almost the same: 22.5 percent in combination with irinotecan and 10.5 percent alone.

Do not use irinotecan if you are pregnant.

Before you are treated with irinotecan, tell your doctor about all other cancer medicines you have recently used.

The body breaks down irinotecan (Camptosar) to get rid of it.

Otherwise, the improvements later seen might be due solely to irinotecan, not Erbitux.

The new trial, with 209 patients, was intended to test how Avastin worked in those who could not tolerate irinotecan.

Avoid using a laxative or stool softener during treatment with irinotecan.

The company reported tumor shrinkage in 22.5 percent of the patients, who were given both Erbitux and irinotecan.

The substitution of irinotecan for etoposide has yielded conflicting results.

You should not breast-feed while you are using irinotecan.

Combined vincristine/irinotecan has been used with some success.

New chemotherapy drugs called irinotecan and oxaliplatin have extended that to a year and a half.

To make sure you can safely receive irinotecan, tell your doctor if you have any of these other conditions:

When used in conjunction with a standard chemotherapy treatment, irinotecan, 22.9% of patients responded and tumor growth was delayed by approximately 4.1 months.

It is not known whether irinotecan passes into breast milk or if it could harm a nursing baby.